Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Retifanlimab-dlwr 500 Mg/20ml Iv Soln (CDM CP17736969425071678) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved July 3, 2026 , from http://ppman.hank.ai/transparency/procedure/CP17736969425071678/by-state?code_type=CDM
“Retifanlimab-dlwr 500 Mg/20ml Iv Soln (CDM CP17736969425071678) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/CP17736969425071678/by-state?code_type=CDM. Accessed
July 3, 2026 .
“Retifanlimab-dlwr 500 Mg/20ml Iv Soln (CDM CP17736969425071678) by State,” HANK Price Transparency ,
accessed July 3, 2026 ,
http://ppman.hank.ai/transparency/procedure/CP17736969425071678/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
CP17736969425071678 — Retifanlimab-dlwr 500 Mg/20ml IV Soln
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$13,103
National median
$11,563 – $15,910
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for CP17736969425071678 (CDM), with interquartile range
State Median p25 p75
ND $13,103 $11,563 $15,910